Impact News +++ Scor beats profit estimates on strong underwriting results (Investing.com) +++ SCOR Aktie +4,33%

ARBUTUS Aktie

>ARBUTUS Aktienkurs

3.814 EUR -5.6% (TradegateBSX)

Ask: 3.9 EUR / 808 Stück

Bid: 3.7 EUR / 836 Stück

Tagesumsatz: 5354 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ARBUTUS Aktie über LYNX handeln

Intraday

1 Jahr

>ARBUTUS Performance

1 Woche: +2,6%

1 Monat: +14,3%

3 Monate: +6,9%

6 Monate: +14,7%

1 Jahr: +18,5%

laufendes Jahr: -2,8%

>ARBUTUS Aktie

Name:

ARBUTUS BIOPHARMA

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA03879J1003 / A14XMD

Symbol/ Ticker:

I9DN (Frankfurt) / ABUS (NASDAQ)

Kürzel:

FRA:I9DN, ETR:I9DN, I9DN:GR, NASDAQ:ABUS

Index:

Webseite:

https://www.arbutusbio.co..

Profil:

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The company's p..
>Volltext..

Marktkapitalisierung:

774.63 Mio. EUR

Unternehmenswert:

698.1 Mio. EUR

Umsatz:

12.6 Mio. EUR

EBITDA:

-26.45 Mio. EUR

Nettogewinn:

-36.46 Mio. EUR

Gewinn je Aktie:

-0.19 EUR

Schulden:

3.97 Mio. EUR

Liquide Mittel:

19.33 Mio. EUR

Operativer Cashflow:

-38.55 Mio. EUR

Bargeldquote:

18.08

Umsatzwachstum:

105.56%

Gewinnwachstum:

47.7%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

ARBUTUS

Letzte Datenerhebung:

04.03.26

>ARBUTUS Kennzahlen

Aktien/ Unternehmen:

Aktien: 192.32 Mio. St.

Frei handelbar: 78.12%

Leerverk. Aktien: 7.8%

Rückkaufquote: -0.52%

Mitarbeiter: 44

Umsatz/Mitarb.: 0.12 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 53.97%

Bewertung:

KGV: -

KGV lG: -

KUV: 58.47

KBV: 11.32

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 95.31%

Gewinnmarge: -289.45%

Operative Marge: -214.67%

Managementeffizenz:

Gesamtkaprendite: -35.5%

Eigenkaprendite: -45.88%

>ARBUTUS Peer Group

Gesundheit

>ARBUTUS Chart & Kurs - NASDAQ

>ARBUTUS News

03.03.26 - 23:21	Moderna surges after hours on patent settlement with Arbutus and Genevant (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 23:18	Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus (AFX)
	WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary......

03.03.26 - 22:54	Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant (WSJ EN)
	The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor....

03.03.26 - 22:48	Moderna to Pay Almost $1 Billion to Settle Arbutus Litigation (Bloomberg)
	Moderna Inc. agreed to pay $950 million to settle all litigation worldwide with Arbutus Biopharma Corp. and Genevant Sciences GmbH over the company's existing and future vaccines, with no future royalties owed....

03.03.26 - 22:31	Moderna, Inc.: Moderna Resolves Global Patent Litigation with Arbutus/Genevant (Accesswire)
	Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026District Court's Section 1498 decision to be appealed to the Federal C......

03.03.26 - 22:17

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....

03.03.26 - 22:17

Roivant Announces Genevant Sciences′ and Arbutus Biopharma′s $2.25 Billion Global Settlement With Moderna (GlobeNewswire EN)

BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology in its COVID-19 vaccines, including Spikevax®....

18.02.26 - 15:48	Moderna dealt blows in ongoing patent dispute with Arbutus (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.02.26 - 20:24	Arbutus jumps on ruling in patent dispute with Moderna (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.01.26 - 14:45	Arbutus falls as patent dispute with Moderna hits EU snag (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.01.26 - 13:54	Widerruf von Schlüsselpatent: Aktie von Arbutus Biopharma fällt um 7 % (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.01.26 - 19:45	Arbutus (ABUS) Upgraded to Buy: Here′s What You Should Know (Zacks)
	Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

13.11.25 - 14:06	Arbutus Biopharma GAAP EPS of -$0.04 misses by $0.01, revenue of $0.53M misses by $0.42M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.25 - 13:33	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update....

06.08.25 - 21:24	Arbutus (ABUS) Q2 Revenue Surges 529% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 16:00	Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates (Zacks)
	Arbutus (ABUS) delivered earnings and revenue surprises of +150.00% and +496.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

06.08.25 - 13:48	Arbutus Biopharma GAAP EPS of $0.01 beats by $0.06, revenue of $10.74M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 13:36	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran...

25.06.25 - 13:33	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus (GlobeNewswire EN)
	Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China...

06.06.25 - 13:42	DataMetrex AI Ltd.: Datametrex Acquires Arbutus Health And Wellness Inc. (Accesswire)
	TORONTO, ON / ACCESS Newswire / June 6, 2025 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that further to its news release dated......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer ein blindes Pferd verkaufen will, lobt die Füße. - Bauernregel - Bauernweisheit

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram